RT Journal Article
SR Electronic
T1 Ethnic disparities in incident SARS-CoV-2 infections became wider during the second wave of SARS-CoV-2 in Amsterdam, the Netherlands: a population-based longitudinal study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.21.21260956
DO 10.1101/2021.07.21.21260956
A1 Coyer, Liza
A1 Boyd, Anders
A1 Schinkel, Janke
A1 Agyemang, Charles
A1 Galenkamp, Henrike
A1 Koopman, Anitra D M
A1 Leenstra, Tjalling
A1 van Duijnhoven, Yvonne T H P
A1 van Charante, Eric P Moll
A1 van den Born, Bert-Jan H
A1 Lok, Anja
A1 Verhoeff, Arnoud
A1 Zwinderman, Aeilko H
A1 Jurriaans, Suzanne
A1 Stronks, Karien
A1 Prins, Maria
YR 2021
UL http://medrxiv.org/content/early/2021/07/24/2021.07.21.21260956.abstract
AB Background Surveillance data in high-income countries have reported more frequent SARS-CoV-2 diagnoses in ethnic minority groups. We examined the cumulative incidence of SARS-CoV-2 and its determinants in six ethnic groups in Amsterdam, the Netherlands.Methods We analyzed participants enrolled in the population-based HELIUS cohort, who were tested for SARS-CoV-2-specific antibodies and answered COVID-19-related questions between June 24-October 9, 2020 (after the first wave) and November 23, 2020-March 31, 2021 (during the second wave). We modeled SARS-CoV-2 incidence from January 1, 2020-March 31, 2021 using Markov models adjusted for age and sex. We compared incidence between ethnic groups over time and identified determinants of incident infection within ethnic groups.Findings 2,497 participants were tested after the first wave; 2,083 (83·4%) were tested during the second wave. Median age at first visit was 54 years (interquartile range=44-61); 56·6% were female. Compared to Dutch-origin participants (15·9%), cumulative SARS-CoV-2 incidence was higher in participants of South-Asian Surinamese (25·0%; adjusted hazard ratio [aHR]=1·66;95%CI=1·16-2·40), African Surinamese (28·9%;aHR=1·97;95%CI=1·37-2·83), Turkish (37·0%;aHR=2·67;95%CI=1·89-3·78), Moroccan (41·9%;aHR=3·13;95%CI=2·22-4·42), and Ghanaian (64·6%;aHR=6·00;95%CI=4·33-8·30) origin. Compared to those of Dutch origin, differences in incidence became wider during the second versus first wave for all ethnic minority groups (all p for interaction<0.05), except Ghanaians. Having household members with suspected SARS-CoV-2 infection, larger household size, and low health literacy were common determinants of SARS-CoV-2 incidence across groups.Interpretation SARS-CoV-2 incidence was higher in the largest ethnic minority groups of Amsterdam, particularly during the second wave. Prevention measures, including vaccination, should be encouraged in these groups.Funding ZonMw, Public Health Service of Amsterdam, Dutch Heart Foundation, European Union, European Fund for the Integration of non-EU immigrants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by ZonMw (10430022010002) and the Public Health Service of Amsterdam. The HELIUS study is conducted by Amsterdam UMC, location Academic Medical Center and the Public Health Service of Amsterdam. Both organizations provided core support for HELIUS. The HELIUS study is also funded by the Dutch Heart Foundation (2010 T084), ZonMw (200500003), the European Union (FP-7) (278901), and the European Fund for the Integration of non-EU immigrants (EIF) (2013EIF013).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the HELIUS study was obtained from the Academic Medical Center Ethical Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe HELIUS data are owned by the Amsterdam UMC, location AMC, in Amsterdam, The Netherlands. Any researcher can request the data by submitting a proposal to the HELIUS Executive Board as outlined at http://www.heliusstudy.nl/en/researchers/collaboration, by email: heliuscoordinator{at}amsterdamumc.nl. The HELIUS Executive Board will check proposals for compatibility with the general objectives, ethical approvals and informed consent forms of the HELIUS study. There are no other restrictions to obtaining the data and all data requests will be processed in the same manner.